Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26244
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wijns, William | - |
dc.contributor.author | VROLIX, Mathias | - |
dc.contributor.author | Verheye, Stefan | - |
dc.contributor.author | Schoors, Danny | - |
dc.contributor.author | Slagboom, Ton | - |
dc.contributor.author | Gosselink, Marcel | - |
dc.contributor.author | BENIT, Edouard | - |
dc.contributor.author | Kandzari, David | - |
dc.contributor.author | Donohoe, Dennis | - |
dc.contributor.author | Ormiston, John | - |
dc.date.accessioned | 2018-06-29T08:32:34Z | - |
dc.date.available | 2018-06-29T08:32:34Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | EUROINTERVENTION, 13(18), p. E2147-E2151 | - |
dc.identifier.issn | 1774-024X | - |
dc.identifier.uri | http://hdl.handle.net/1942/26244 | - |
dc.description.abstract | Aims: The aim of this study was to evaluate the five-year clinical results of a sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating designed for sustained drug delivery during and after rapid polymer dissolution. Methods and results: The five-year results from the DESSOLVE I and II trials including major adverse cardiac events (MACE), target lesion failure (TLF), target vessel failure (TVF), and stent thrombosis (ST) at five-year follow-up are reported. In DESSOLVE I, 10.3% of patients receiving the MiStent SES (3/29) had a MACE event up to five years without TLF. In DESSOLVE II, 15.1% of patients in the MiStent group (18/119) had a five-year MACE event compared to 22.0% of patients in the Endeavor group (p= 0.295). TLF was 9.2% in the MiStent group and 8.5% in the Endeavor group (p= 1.00). TVF was 10.1% for MiStent versus 15.3% for Endeavor (p= 0.331). Up to five-year follow-up, the MiStent SES has continued to demonstrate low rates of TLR across DESSOLVE I (0.0%) and DESSOLVE II (3.4%). No ST was reported with the MiStent up to five years in the DESSOLVE I trial. In DESSOLVE II, definite or probable ST was 0.0% with MiStent and 1.7% with Endeavor up to five years. Conclusions: The MiStent SES demonstrated long-term safety and effectiveness with low rates of fiveyear MACE, TLF, and TVF across these two clinical trials. | - |
dc.description.sponsorship | This trial is sponsored by Micell Technologies, Durham, NC, USA. | - |
dc.language.iso | en | - |
dc.subject.other | clinical research; clinical trials; drug-eluting stent; multiple vessel disease; single vessel disease | - |
dc.title | Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | E2151 | - |
dc.identifier.issue | 18 | - |
dc.identifier.spage | E2147 | - |
dc.identifier.volume | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Wijns, W (reprint author), Natl Univ Ireland Galway, Lambe Inst Translat Med, Floor 2,Univ Rd, Galway H91 TK33, Ireland. William.Wyns@nuigalway.ie | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.class | dsPublValOverrule/author_version_not_expected | - |
local.class | dsPublValOverrule/internal_author_not_expected | - |
local.class | IncludeIn-ExcludeFrom-List/ExcludeFromFRIS | - |
dc.identifier.doi | 10.4244/EIJ-D-17-00230 | - |
dc.identifier.isi | 000430649300013 | - |
item.accessRights | Closed Access | - |
item.contributor | Wijns, William | - |
item.contributor | VROLIX, Mathias | - |
item.contributor | Verheye, Stefan | - |
item.contributor | Schoors, Danny | - |
item.contributor | Slagboom, Ton | - |
item.contributor | Gosselink, Marcel | - |
item.contributor | BENIT, Edouard | - |
item.contributor | Kandzari, David | - |
item.contributor | Donohoe, Dennis | - |
item.contributor | Ormiston, John | - |
item.fullcitation | Wijns, William; VROLIX, Mathias; Verheye, Stefan; Schoors, Danny; Slagboom, Ton; Gosselink, Marcel; BENIT, Edouard; Kandzari, David; Donohoe, Dennis & Ormiston, John (2018) Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials. In: EUROINTERVENTION, 13(18), p. E2147-E2151. | - |
item.fulltext | No Fulltext | - |
crisitem.journal.issn | 1774-024X | - |
crisitem.journal.eissn | 1969-6213 | - |
Appears in Collections: | Research publications |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.